Overview
- Succintly combines the most current research on lung cancer from epidemiology to recent breakthroughs in personalized therapies
- Explores current targets, molecular profiling and biomarkers in lung cancer
- Integrates basic research and clinical implications, fostering cross-disciplinary research and creating wide appeal
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 893)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (11 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
Reviews
“The aim of this book is to discuss current knowledge about lung cancer with a specific focus on non-small-cell lung cancer (NSCLC). … The intended audience is established researchers, clinicians, healthcare professionals, and students in the medical and scientific community. … The authors have successfully compiled a well-written, comprehensive, and robust book about NSCLC … .” (Karen L. Reckamp, Doody’s Book Reviews, August, 2016)
Editors and Affiliations
About the editors
Shirish M. Gadgeel, M.D. a Professor in the Department of Oncology at Karmanos Institute/Wayne State University in Detroit. He is the co-leader of the Molecular Therapeutics Program of Karmanos Cancer Institute and the leader of the Multidisciplinary Thoracic Oncology team. Dr. Gadgeel is a member of several professional societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He currently serves on the Editorial Board of the journals Cancer and Clinical Lung Cancer. Dr. Gadgeel is a Principal Investigator of several trials focused on the treatment of Lung Cancer, and has published more than 80 scientific papers
Bibliographic Information
Book Title: Lung Cancer and Personalized Medicine
Book Subtitle: Current Knowledge and Therapies
Editors: Aamir Ahmad, Shirish Gadgeel
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-3-319-24223-1
Publisher: Springer Cham
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2016
Hardcover ISBN: 978-3-319-24221-7Published: 18 December 2015
Softcover ISBN: 978-3-319-79592-8Published: 27 March 2019
eBook ISBN: 978-3-319-24223-1Published: 14 December 2015
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: XIII, 228
Number of Illustrations: 12 b/w illustrations, 14 illustrations in colour
Topics: Cancer Research, Molecular Medicine, Internal Medicine, Oncology